Does long-term efficacy differ between infliximab and adalimumab after 1 year of continuous administration?: A STROBE-compliant retrospective cohort study

Although biologics are important inflammatory bowel disease therapies, loss of response (LOR) remains problematic. We evaluated LOR to biologics in our Crohn disease (CD) patients receiving biologics. Of 137 biologic-treated CD patients, 68 continuously receiving the same biologic type for at least...

Descripción completa

Detalles Bibliográficos
Autores principales: Otake, Haruka, Matsumoto, Satohiro, Mashima, Hirosato
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2017
Materias:
4500
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406077/
https://www.ncbi.nlm.nih.gov/pubmed/28422861
http://dx.doi.org/10.1097/MD.0000000000006635

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5406077/
https://www.ncbi.nlm.nih.gov/pubmed/28422861
http://dx.doi.org/10.1097/MD.0000000000006635

Ejemplares similares